269 related articles for article (PubMed ID: 35866394)
1. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
Nel I; Herzog H; Aktas B
Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
[TBL] [Abstract][Full Text] [Related]
2. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
3. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Wimberger P; Blohmer JU; Krabisch P; Link T; Just M; Sinn BV; Simon E; Solbach C; Fehm T; Denkert C; Kühn C; Rhiem K; Tesch H; Kümmel S; Petzold A; Stötzer O; Meisel C; Kuhlmann JD; Nekljudova V; Loibl S
Breast Cancer Res; 2023 Mar; 25(1):32. PubMed ID: 36978142
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
[TBL] [Abstract][Full Text] [Related]
6. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
7. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
[TBL] [Abstract][Full Text] [Related]
8. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
9. Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer.
Barnell EK; Fisk B; Skidmore ZL; Cotto KC; Basu A; Anand A; Richters MM; Luo J; Fronick C; Anurag M; Fulton R; Ellis MJ; Griffith OL; Griffith M; Ademuyiwa FO
Sci Rep; 2022 Oct; 12(1):17732. PubMed ID: 36273232
[TBL] [Abstract][Full Text] [Related]
10. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM; Brown Swigart L; Ahmed Z; Sayaman RW; Renner D; Kalashnikova E; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Asare S; Liu MC; Albain K; Chien AJ; Forero-Torres A; Isaacs C; Nanda R; Tripathy D; Rodriguez A; Sethi H; Aleshin A; Rabinowitz M; Perlmutter J; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Cancer Cell; 2023 Jun; 41(6):1091-1102.e4. PubMed ID: 37146605
[TBL] [Abstract][Full Text] [Related]
12. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Cavallone L; Aguilar-Mahecha A; Lafleur J; Brousse S; Aldamry M; Roseshter T; Lan C; Alirezaie N; Bareke E; Majewski J; Ferrario C; Hassan S; Discepola F; Seguin C; Mihalcioiu C; Marcus EA; Robidoux A; Roy JA; Pelmus M; Basik M
Sci Rep; 2020 Sep; 10(1):14704. PubMed ID: 32895401
[TBL] [Abstract][Full Text] [Related]
14. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
Sun Y; Zhu C; Xu F; Cui S; Guan X
Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
[TBL] [Abstract][Full Text] [Related]
17. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
[TBL] [Abstract][Full Text] [Related]
19. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
